Defining the Ideal Cranial Vault Height Ratio Via Morphometric Analysis: A Preliminary Study
Listen to this summary
The authors aimed to determine the optimal cranial vault height ratio (CVHR) in Chinese women through morphometric and perceptual analyses. Their study found that a CVHR of 0.60 to 0.65 was perceived as most attractive, with variations in preference noted between general respondents and aesthetic practitioners. This research provides a preliminary quantitative reference for aesthetic cranial contouring procedures.
This is one of 33,000+ journals available on OSLR. Try it free for 14 days.
Free 14-day trial. 33,000+ journals. Cancel anytime.
More from Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
View all →Jun 9, 2026 · Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
Novel 1550-nm Nonablative Resurfacing Laser With Focal Point Technology Improves Fine Lines and Wrinkles With High Energy Delivery
Jun 3, 2026 · Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
Lasers and Acquired Melanocytic Nevi: A Systematic Review
More in Dermatology
View all →Aug 6, 2026 · Lancet (London, England)
[<sup>177</sup>Lu]Lu-PSMA-617 in patients with PSMA-positive metastatic androgen pathway modulator-naive/sensitive prostate cancer (PSMAddition): a phase 3 randomised, controlled trial
Aug 5, 2026 · The New England journal of medicine
Syncope
Jul 31, 2026 · Lancet (London, England)
Multivessel coronary artery bypass grafting via small thoracotomy versus sternotomy (MIST): an investigator-initiated, international, open-label, randomised controlled trial
Jul 30, 2026 · Lancet (London, England)
Efficacy and safety of once-daily oral zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in adults with type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial
Jul 30, 2026 · Lancet (London, England)
Efficacy and safety of once-weekly subcutaneous zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial
Jul 29, 2026 · Lancet (London, England)
Deramiocel heart-derived cellular therapy in advanced Duchenne muscular dystrophy (HOPE-3): a phase 3, randomised, double-blind, placebo-controlled trial
"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."
Dr. Jennifer Thompson
Portland, OR
Stay current without falling behind
33,000+ journals. 3-minute audio summaries. Free for 14 days.
